Misplaced Pages

Tunlametinib

Clinical data
Other names	HL-085
ATC code	None
Legal status
Legal status	Rx in China
Identifiers
IUPAC name 4-Fluoro-5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide
CAS Number	1801756-06-8
PubChem CID	71621329
ChemSpider	115006753
UNII	IF25NR1PV3
ChEMBL	ChEMBL5095241
Chemical and physical data
Formula	C16H12F2IN3O3S
Molar mass	491.25 g·mol

Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhbitor of mitogen-activated protein kinase kinase.

In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.

It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.

References

1. "Tunlametinib". NCI Drug Dictionary. National Cancer Institute.
2. "Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy". 18 March 2024.
3. Keam SJ (2024). "Tunlametinib: First Approval". Drugs. 84 (8): 1005–1010. doi:10.1007/s40265-024-02072-x. PMID 39034326.
4. Shi Y, Han X, Zhao Q, Zheng Y, Chen J, Yu X, et al. (2024). "Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: An open-label, single-arm, multicenter, phase I study". Experimental Hematology & Oncology. 13 (1): 60. doi:10.1186/s40164-024-00528-0. PMC 11167782. PMID 38867257.

• Medicine

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Benzothiazoles
• Fluoroarenes
• Iodoarenes
• Glycol ethers
• Carboxamides
• Antineoplastic and immunomodulating drug stubs